Innovent Signs a License Agreement with Eli Lilly to Develop and Commercialize OXM3 in China

Shots:

• Innovent and Eli Lilly entered into a licensing agreement to develop & commercialize novel diabetic therapy, OXM3 in China
• The license agreement will strengthen Innovent’s diabetic portfolio with the addition of Eli Lilly’s mid-clinical stage metabolic disease asset, OXM3
• OXM3 is an oxyntomodulin analog, binds to & activates GLP-1 and the glucagon receptor demonstrating wt. loss and improvement in glycemic control in its early clinical studies and has the potential to be developed for diabetes, obesity and NASH

Click here to­ read full press release/ article | Ref: Innovent | Image: GMP News